FinkelsteinE.S., JekelJ., TroidleL., Gorban–BrennanN., FinkelsteinF.O., BiaF.J.Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis.Am J Kidney Dis2002; 39: 1278–86.
6.
MujaisS.Microbiology and outcomes of peritonitis in North America.Kidney Int Suppl2006; (103): S55–62.
7.
WitowskiJ., KorybalskaK., KsiazekK., Wisniewska–ElnurJ., JörresA., LageC.Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.Nephrol Dial Transplant2004; 19: 917–24.
8.
DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
9.
BenderF.H., BernardiniJ., PirainoB.Prevention of infectious complications in peritoneal dialysis: best demonstrated practices.Kidney Int Suppl2006; (103): S44–54.
10.
VychytilA., RemónC., MichelC., WilliamsP., Rodríguez– CarmonaA., MarrónB.Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study.Nephrol Dial Transplant2008; 23: 3711–19.
11.
MontenegroJ., SarachoR., GallardoI., MartínezI., MuñozR., QuintanillaN.Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis.Nephrol Dial Transplant2007; 22: 1703–8.
12.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
13.
FurkertJ., ZeierM., SchwengerV.Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates.Perit Dial Int2008; 28: 637–40.
CozensR.M., TuomanenE., ToschW., ZakO., SuterJ., TomaszA.Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat.Antimicrob Agents Chemother1986; 29: 797–802.
16.
TuomanenE., CozensR., ToschW., ZakO., TomaszA.The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth.J Gen Microbiol1986; 132: 1297–304.
17.
ClouseF.L., HovdeL.B., RotschaferJ.C.In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.Antimicrob Agents Chemother2007; 51: 4521–4.
18.
DasguptaM.K., WardK., NobleP.A., LarabieM., CostertonJ.W.Development of bacterial biofilms on Silastic catheter materials in peritoneal dialysis fluid.Am J Kidney Dis1994; 23: 709–16.
19.
DasguptaM.K.Biofilms and infection in dialysis patients.Semin Dial2002; 15: 338–46.
20.
ReidG., KhouryA.E., PrestonC.A., CostertonJ.W.Influence of dextrose dialysis solutions on adhesion of Staphylococcus aureus and Pseudomonas aeruginosa to three catheter surfaces.Am J Nephrol1994; 14: 37–40.
